MarketCapExport financials
Syros Pharmaceuticals (SYRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Syros Pharmaceuticals Income Statement 2023-2011 | SYRS
Brief overview of revenue and earnings at Syros Pharmaceuticals
The conclusions below are based on five years of reported results. Syros Pharmaceuticals reported revenue of $893 thousand in 2018 and $9.9 million by 2023. Across the full period, sales moved by +1012.7%; the average annual rate was 61.9%. This pace points to rapid expansion of the business.
The operating result measured by EBITDA moved from −62.7 million dollars to −127 million dollars, or −102.2%. The operating result developed less favorably than sales. The EBITDA share of revenue changed from −7020.4% to −1275.5%. A wider margin confirms stronger operating efficiency.
The net financial result changed from −$62.3 million to −$165 million. Larger losses indicate rising pressure on the business.
Financial takeaway
The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by positive operating leverage and revenue expansion. The most visible risks are a narrow EBITDA buffer and declining net profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Syros Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
165 M | 46 M | 8.07 M | 38.7 M | 235 M | 222 M | 268 M | 140 M | - | - | - | - | - |
Shares |
28.3 M | 12.6 M | 6.25 M | 4.61 M | 40.2 M | 32.7 M | 25.4 M | 12.7 M | 1.98 M | 1.53 M | - | - | - |
Historical Prices |
5.84 | 3.64 | 1.29 | 8.4 | 5.85 | 6.79 | 10.5 | 11.1 | - | - | - | - | - |
Net Income |
-165 M | -94.7 M | -86.6 M | -84 M | -75.4 M | -62.3 M | -54 M | -47.7 M | -29.8 M | -13.4 M | - | - | - |
Revenue |
9.94 M | 14.9 M | 23.5 M | 15.1 M | 508 K | 893 K | 1.1 M | 317 K | 317 K | - | - | - | - |
Operating Income |
-129 M | -136 M | -99.4 M | -82.3 M | -77.7 M | -64.3 M | -54.7 M | -48 M | -29.8 M | -13.4 M | - | - | - |
Interest Expense |
5.13 M | 4.13 M | 3.91 M | 1.79 M | 72 K | 1 K | 676 K | 220 K | 2 K | 4 K | - | - | - |
EBITDA |
-127 M | -133 M | -96.7 M | -79.5 M | -75.2 M | -62.7 M | -53.2 M | -46.7 M | -29.2 M | -13.2 M | - | - | - |
Operating Expenses |
139 M | 151 M | 123 M | 97.4 M | 79.7 M | 66.3 M | 55.8 M | 48.3 M | 30.1 M | 13.4 M | - | - | - |
General and Administrative Expenses |
28.3 M | 29.3 M | 23 M | 21.3 M | 21.5 M | 16.2 M | 13.9 M | 10.5 M | 5.73 M | 2.51 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Syros Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
39.3 M | 39.3 M | 39 M | 26.4 M | 28 M | 27.9 M | 27.8 M | 20.3 M | 9.42 M | 63.8 M | 63.1 M | 6.2 M | 62.9 M | 62.9 M | 61.4 M | 48.8 M | 45.8 M | 45.7 M | 43.9 M | 42.9 M | 42.4 M | 41.7 M | 33.8 M | 33.7 M | 33.7 M | 32.9 M | 30.3 M | 26.3 M | 26.3 M | 25.6 M | 23.4 M | 23.4 M | 22 M | 2.55 M | 2.39 M | 2.32 M | 2.15 M | 1.76 M | 1.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-6.4 M | -23.3 M | -3.71 M | - | -40.1 M | -36.3 M | -23.8 M | - | -30.3 M | -34.5 M | -25.1 M | - | -26 M | -22.5 M | -14.2 M | -30.1 M | -19.5 M | -17.2 M | -17.2 M | -19.7 M | -19.8 M | -19.5 M | -16.5 M | -18 M | -15.7 M | -14 M | -14.5 M | -15.3 M | -13.8 M | -13.4 M | -11.5 M | -11 M | -14.2 M | -12 M | -47.7 M | -10.7 M | -29.8 M | -29.8 M | -4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
3.76 M | 2.83 M | 2.95 M | - | 3.76 M | 2.83 M | 2.95 M | - | 3.89 M | 6.28 M | 5.47 M | - | 5.7 M | 5.16 M | 4.83 M | 5.7 M | 3.83 M | 3.19 M | 2.38 M | 508 K | 558 K | 462 K | 454 K | 893 K | 412 K | 375 K | 370 K | - | 1.1 M | 1.1 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-26.2 M | -27.4 M | -30.9 M | - | -34.6 M | -34 M | -33.2 M | - | -39.5 M | -33.8 M | -26.7 M | - | -26.9 M | -26.1 M | -20.9 M | -29.2 M | -19 M | -16.7 M | -17.3 M | -20.2 M | -20.4 M | -20.2 M | -17 M | -18.6 M | -16.3 M | -14.5 M | -14.8 M | -15.5 M | -14 M | -13.5 M | -11.6 M | -11 M | -14.2 M | -12.1 M | -10.6 M | -10.7 M | -8.46 M | -6.1 M | -4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 1.38 M | 1.31 M | - | 1.3 M | 1.28 M | 1.22 M | - | 1.05 M | 981 K | 976 K | - | 984 K | 969 K | 967 K | 541 K | -489 K | -455 K | 113 K | 20 K | 596 K | 753 K | 512 K | 575 K | 583 K | 501 K | 358 K | 218 K | 215 K | 145 K | 98 K | 80 K | 48 K | 44 K | 48 K | - | 2 K | -2 K | 4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-25.2 M | -26.8 M | -30.6 M | - | -32.7 M | -32.7 M | -32.6 M | - | -37.5 M | -32.4 M | -26 M | - | -24.9 M | -24.8 M | -20.3 M | -29.2 M | -16.9 M | -15.4 M | -16.7 M | -20.2 M | -18.7 M | -19.1 M | -16.5 M | -18.6 M | -15.1 M | -13.8 M | -14.4 M | -15.5 M | -12.9 M | -12.8 M | -11.2 M | -11 M | -13.3 M | -11.4 M | -10.3 M | -10.7 M | -8.09 M | -5.91 M | -4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
26.2 M | 27.4 M | 30.9 M | - | 38.4 M | 36.8 M | 36.2 M | - | 43.3 M | 40 M | 32.1 M | - | 32.6 M | 31.3 M | 25.8 M | 34.9 M | 22.8 M | 19.9 M | 19.7 M | 20.7 M | 20.9 M | 20.7 M | 17.4 M | 19.5 M | 16.7 M | 14.9 M | 15.2 M | 15.5 M | 14 M | 13.5 M | 12.7 M | 11.4 M | 14.2 M | 12.1 M | 10.6 M | 10.7 M | 8.46 M | 6.41 M | 4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.66 M | 5.46 M | 6.27 M | - | 7.76 M | 7.22 M | 7.4 M | - | 8.08 M | 6.94 M | 6.95 M | - | 5.35 M | 5.52 M | 5.74 M | 5.89 M | 5.15 M | 5.13 M | 5.15 M | 6.4 M | 5.02 M | 5.2 M | 4.86 M | 4.37 M | 3.88 M | 3.84 M | 4.08 M | 3.74 M | 3.59 M | 3.47 M | 3.09 M | 2.92 M | 2.63 M | 2.54 M | 2.37 M | 2.31 M | 1.6 M | 984 K | 836 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Syros Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
$ 1.43 | 0.54 % | $ 128 M |  France |
 |
NextCure
NXTC
|
$ 6.24 | 4.56 % | $ 17.7 M |  USA |
 |
BeyondSpring
BYSI
|
$ 0.56 | 3.09 % | $ 23 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 6.71 | 10.32 % | $ 312 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.5 | 1.75 % | $ 47.9 M |  Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.49 | 0.04 % | $ 17.1 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 128.75 | 0.2 % | $ 8.19 B | USA |
 |
Passage Bio
PASG
|
$ 3.5 | 4.44 % | $ 11.2 M | USA |
 |
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 80.14 | 3.04 % | $ 4.02 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.65 | 1.67 % | $ 162 M | USA |
|
Immatics N.V.
IMTX
|
$ 6.73 | 2.0 % | $ 823 M |  Germany |
 |
Immunic
IMUX
|
$ 6.97 | 0.56 % | $ 1.09 B | USA |
 |
Immunovant
IMVT
|
$ 26.73 | 0.57 % | $ 4.88 B | USA |
 |
MediciNova
MNOV
|
$ 1.42 | 0.69 % | $ 69.7 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 13.62 | 3.59 % | $ 4.87 M | USA |
|
Rezolute
RZLT
|
$ 3.58 | 0.12 % | $ 372 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Canada |
 |
Krystal Biotech
KRYS
|
$ 316.58 | 0.82 % | $ 9.16 B | USA |
 |
Nektar Therapeutics
NKTR
|
$ 35.78 | 2.25 % | $ 604 M | USA |
 |
NanoViricides
NNVC
|
$ 1.38 | 0.73 % | $ 27.9 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.64 | 1.33 % | $ 5.19 B |  Spain |
 |
Nurix Therapeutics
NRIX
|
$ 24.42 | 0.12 % | $ 2.12 B | USA |
 |
Ocugen
OCGN
|
$ 0.78 | 0.06 % | $ 244 M | USA |
 |
Oragenics
OGEN
|
$ 0.43 | 1.69 % | $ 928 K | USA |
 |
Omeros Corporation
OMER
|
$ 16.2 | 1.95 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 12.35 | 10.18 % | $ 1.08 B | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.86 | 3.06 % | $ 48 M | USA |
 |
Alkermes plc
ALKS
|
$ 41.22 | 2.79 % | $ 6.79 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 210.23 | 2.28 % | $ 12.8 B | Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.87 | 0.05 % | $ 5.21 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 22.12 | 1.26 % | $ 2.38 B | USA |
|
Larimar Therapeutics
LRMR
|
$ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
$ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
$ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 21.3 | 4.46 % | $ 1.02 T | France |
 |
Syndax Pharmaceuticals
SNDX
|
$ 12.9 | 0.89 % | $ 1.12 B | USA |
 |
Soligenix
SNGX
|
$ 0.35 | 1.67 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.42 | 0.71 % | $ 1.24 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.45 | 1.6 % | $ 1.52 B | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 17.1 | 0.03 % | $ 1.71 B | USA |